



Appendix 1 (as supplied by the authors): Modified Hodge Test results for the NDM-1-producing isolates identified in case one (A, C) and case two (B, D). If the Modified Hodge Test shows “enhanced growth” of the indicator organism (*E. coli* ATCC 25922) around the test organism streak at the intersection of the streak and the zone of inhibition of the indicator organism, this should be interpreted as “positive for carbapenemase production”, while “no enhanced growth” should be interpreted as “negative for carbapenemase production”.¹ The indicator organism is shown with expected ertapenem zone of inhibition. Negative KP1706 (*K. pneumoniae* ATCC BAA-1706) and positive KP1705 (*K. pneumoniae* ATCC BAA-1705) controls are as shown. Case one (A) and case two (B) test isolate streaks are shown. Both test results were interpreted as negative by the clinical laboratories involved in these cases. In retrospect, both can be seen to be subtly positive with “enhanced growth” of the indicator organism detected as flattening or loss of concavity of the zone of inhibition at the intersection of the test isolate streak and zone of inhibition, a finding that can be easily missed especially when compared against the positive control. Duplicate images are shown for case one (C) and case two (D) with the subtly positive “enhanced growth” of the indicator organism shown by white arrows above the expected concavity of the zone of inhibition shown by dashed circles. Results were identical for both organisms isolated in case one.



Reference

1. Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement*. CLSI document M100-S21. Wayne (PA): The Institute; 2011.